Market Intelligence, Preclinical Progress, and High-Purity Reagents for Immuno-Oncology, Solid Tumor, and Biomarker Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTPRK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRK ECD-Fc Fusion Protein: High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. HEK293 expressed (native glycosylation). Covers MAM-Ig-FN3 domains. | View PTPRK Products |
| Gene Delivery | PTPRK Promise-ORF / Lentivirus: Full-length ORF for stable cell lines. Preserves native membrane topology for functional assays. | View PTPRK Products |
| Benchmark Ab | Anti-PTPRK Reference Antibody (Research Grade): Recombinant positive control for binding validation and assay standardization. | View PTPRK Products |
| Validator | PTPRK siRNA Set: Validated knockdown sequences for specificity verification and functional baseline establishment. | View PTPRK Products |
| Related Target: PTPRM | R2B subfamily homolog; essential for homophilic binding counter-screening and off-target liability assessment. Forms heterodimers with PTPRK. | View PTPRM Products |
| Related Target: PTPRT | R2B subfamily paralog; required for phosphatase domain selectivity profiling. Tissue distribution complementary to PTPRK. | View PTPRT Products |
| Related Target: EGFR | Biomarker synergy; PTPRK loss drives EGFR hyperactivation. Direct substrate in signaling cascades. | View EGFR Products |
| Related Target: CTNNB1 | Direct interaction partner in cell-cell adhesion signaling; β-catenin linked to Wnt pathway modulation. | View CTNNB1 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native ECD conformation for homophilic adhesion assays | HEK293-expressed PTPRK ECD-Fc with mammalian glycosylation pattern; sequence verified by mass spec; >95% purity; endotoxin <1 EU/µg. |
| R2B subfamily off-target selectivity (PTPRM / PTPRT / PTPRJ) | Human PTPRM and PTPRT recombinant phosphatase domains available with >95% purity; strict sequence identity confirmation; mass spec coverage >90%. |
| Loss-of-function specificity controls | PTPRK siRNA set included for knockdown validation in lentivirus-stable cell lines (KD efficiency >80%). |
| Membrane-topology dependent dimerization / internalization | Lentivirus premade particles for stable HEK293 or CHO cell lines; cell-based assays preserve conformational epitopes. |
| Cross-species evaluation (cyno/mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence verified. |
| Lack of reliable controls | Clinical benchmark antibodies included for assay standardization; high-purity ECD-Fc fusions with native glycosylation. |
| False positives in signaling assays | Validated siRNA for rigorous specificity checks; high-purity recombinant proteins avoid endotoxin interference. |
Live PTPRK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The PTPRK target remains in the emergent discovery phase, with translational programs pivoting from traditional tumor suppressor gene therapy concepts toward extracellular-domain biologics, allosteric phosphatase modulation, and synthetic lethality strategies. As a known tumor suppressor, loss or mutation of PTPRK frequently results in hyperactivation of oncogenic pathways like EGFR and MET. Major players are shifting focus from direct modulation to biomarker-driven clinical trial designs, where PTPRK deficiency predicts sensitivity to specific tyrosine kinase inhibitors. The next wave of R&D targets homophilic disruption and substrate-selective phosphatase inhibition, as well as combinatorial strategies with immune checkpoint inhibitors. Emerging modalities including antibody-drug conjugates (ADCs), bispecific engagers, and targeted protein stabilizers are entering preclinical development, driven by advances in understanding R2B receptor PTP family biology in immuno-oncology and solid tumor adhesion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody / Biologic | Early-stage biotechnology; academic translation centers | Solid Tumors (Colorectal, Melanoma); Immune Modulation | Homophilic adhesion blocking assay (need conformationally intact ECD-Fc) |
| Antibody-Drug Conjugate (ADC) | Emerging biotech; platform expansion programs | Solid Tumors (Colorectal, Lung) | Internalization & bystander effect assay (need high-purity ECD for conjugation optimization) |
| Bispecific / Cell Engager | Platform technology companies; immuno-oncology platforms | Refractory Solid Tumors | Cell surface epitope density mapping (need lentivirus-stable lines for flow cytometry) |
| Phosphatase Inhibitor (Small Molecule) | Structure-based drug design consortia | Oncology; Tumor Microenvironment | Selectivity assay vs. R2B paralogs (need purified PTPRM / PTPRT domains) |
| Targeted Small Molecules (Agonists) | Early-stage biotech | Solid Tumors (Melanoma, Colorectal) | Enzymatic selectivity assay (need high-purity recombinant proteins) |
| Synthetic Lethality (TKIs) | Major pharma | PTPRK-deficient NSCLC | Cellular phenotype assays (need lentivirus for KO cell lines) |
| Biomarker Diagnostic Abs | Diagnostics companies | Prostate & Breast Cancer | Epitope mapping (need sequence verified ECD-Fc) |
Additional TarMart Capabilities
TarMart provides a specification-first product line designed for PTPRK drug discovery: high-purity antigens with native conformation, lentivirus particles for membrane topology preservation, validated siRNAs for specificity controls, and homolog panel proteins for counter-screening. All products are sequence verified, endotoxin controlled (<1 EU/µg), and optimized for cell-based and biochemical assays.